Sanjay Shukla - 10 Nov 2023 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role
President and CEO, Director
Signature
/s/ Nancy E. Denyes, Attorney-in-Fact
Issuer symbol
ATYR
Transactions as of
10 Nov 2023
Net transactions value
+$16,703
Form type
4
Filing time
13 Nov 2023, 16:11:52 UTC
Previous filing
01 Aug 2023
Next filing
12 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LIFE Common Stock Purchase $1,618 +1,422 +1.9% $1.14 77,595 10 Nov 2023 Direct F1
transaction LIFE Common Stock Purchase $15,085 +13,578 +17% $1.11 91,173 13 Nov 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.13 to $1.14 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
F2 Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.09 to $1.13 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.